Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

β-catenin inhibits cell growth of a malignant mesothelioma cell line, NCI-H28, with a 3p21.3 homozygous deletion

Oncogene volume 22, pages 7922–7930 (2003)Cite this article

Abstract

We have found that a malignant mesothelioma cell line, NCI-H28, had a chromosome 3p21.3 homozygous deletion containing the β-catenin gene (CTNNB1), which suggested that the deletion of β-catenin might have a growth advantage in the development of this tumor. To determine whether β-catenin has a growth-inhibitory activity, we transfected wild-type β-catenin, Ser37Cys mutant β-catenin as an activated type, and C-terminus deletion mutant β-catenin that lacks the transcription activity, into the NCI-H28 cells. A non-small cell lung cancer cell line, NCI-H1299, which expressed endogenous β-catenin, was also studied. We tested the localization of exogenous β-catenin in the NCI-H28 cells with immunofluorescence, and found that the wild-type β-catenin and the C-terminus deletion mutant were more strongly expressed in the plasma membrane and cytoplasm than in the nucleus, while the Ser37Cys mutant was more in the nucleus than in the cytoplasm. By using luciferase-reporter assay, the β-catenin/T-cell factor 4-mediated transactivity of the Ser37Cys mutant was shown to be higher than that of the wild-type β-catenin in both cell lines. However, the transactivity of the C-terminus deletion mutant was strongly reduced in both. Colony formation of the NCI-H28 cells was reduced by 50% after transfection with the wild-type β-catenin, and 60% with the Ser37Cys mutant, but only 20% with the C-terminus deletion mutant compared to the vector control. Inhibition of colony formation in NCI-H28 cells was because of apoptosis, manifested by positive staining of Annexin V and TUNEL assays in transfected cells. In contrast, when transfected with the wild-type β-catenin, no significant reduction in colony formation was seen in β-catenin wild-type NCI-H1299 cells. In conclusion, our data indicate that inactivation of β-catenin by a 3p21.3 homozygous deletion might be a crucial event in the development of the mesothelioma NCI-H28 cells. Thus, while β-catenin is well known to be a positive growth-stimulating factor for many human cancers, it can also act as a potential growth suppressor in some types of human cancer cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Ahmed Y, Hayashi S, Levine A and Wieschaus E . (1998). Cell, 93, 1171–1182.

  • Barth AI, Nathke IS and Nelson WJ . (1997). Curr. Opin. Cell Biol., 9, 683–690.

  • Bell DW, Jhanwar SC and Testa JR . (1997). Cancer Res., 57, 4057–4062.

  • Burbee DG, Forgacs E, Zöchbauer-Müller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M and Minna JD . (2001). J. Natl. Cancer Inst., 93, 691–699.

  • Chen JY, Funk WD, Wright WE, Shay JW and Minna JD . (1993). Oncogene, 8, 2159–2166.

  • Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee WC, Altomare DA, Nobori T, Olopade OI, Buckler AJ and Testa JR . (1994). Cancer Res., 54, 5547–5551.

  • Cheng JQ, Lee WC, Klein MA, Cheng GZ, Jhanwar SC and Testa JR . (1999). Genes Chromosomes Cancer, 24, 238–242.

  • Damalas A, Ben-Ze'ev A, Simcha I, Shtutman M, Leal JF, Zhurinsky J, Geiger B and Oren M . (1999). EMBO J., 18, 3054–3063.

  • Dammann R, Li C, Yoon JH, Chin PL, Bates S and Pfeifer GP . (2000). Nature Genet., 25, 315–319.

  • Flejter WL, Li FP, Antman KH and Testa JR . (1989). Genes Chrom. Cancer, 1, 148–154.

  • Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S and Hirohashi S . (1998). Cancer Res., 58, 3526–3528.

  • Gibas Z, Li FP, Antman KH, Bernal S, Stahel R and Sandberg AA . (1986). Cancer Genet. Cytogenet., 20, 191–201.

  • Hagemeijer A, Versnel MA, Van Drunen E, Moret M, Bouts MJ, van der Kwast TH and Hoogsteden HC . (1990). Cancer Genet. Cytogenet., 47, 1–28.

  • Hasegawa S, Sato T, Akazawa H, Okada H, Maeno A, Ito M, Sugitani Y, Shibata H, Miyazaki J, Katsuki M, Yamauchi Y, Yamamura K, Katamine S and Noda T . (2002). Proc. Natl. Acad. Sci. USA, 99, 297–302.

  • Hayashi S, Rubinfeld B, Souza B, Polakis P, Wieschaus E and Levine AJ . (1997). Proc. Natl. Acad. Sci. USA, 94, 242–247.

  • He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW . (1998). Science, 281, 1509–1512.

  • Iwao K, Nakamori S, Kameyama M, Imaoka S, Kinoshita M, Fukui T, Ishiguro S, Nakamura Y and Miyoshi Y . (1998). Cancer Res., 58, 1021–1026.

  • Kim K, Pang KM, Evans M and Hay ED . (2000). Mol. Biol. Cell, 11, 3509–3523.

  • Kinzler KW and Vogelstein B . (1996). Cell, 87, 159–170.

  • Lee WC, Balsara B, Liu Z, Jhanwar SC and Testa JR . (1996). Cancer Res., 56, 4297–4301.

  • Liu C, Kato Y, Zhang Z, Do VM, Yankner BA and He X . (1999). Proc. Natl. Acad. Sci. USA, 96, 6273–6278.

  • Lu YY, Jhanwar SC, Cheng JQ and Testa JR . (1994). Genes Chromosomes Cancer, 9, 76–80.

  • Miyoshi Y, Iwao K, Nagasawa Y, Aihara T, Sasaki Y, Imaoka S, Murata M, Shimano T and Nakamura Y . (1998). Cancer Res., 58, 2524–2527.

  • Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B and Kinzler KW . (1997). Science, 275, 1787–1790.

  • Polakis P . (2000). Genes Dev., 14, 1837–1851.

  • Popescu NC, Chahinian AP and DiPaolo JA . (1988). Cancer Res., 48, 142–147.

  • Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S and Polakis P . (1996). Science, 272, 1023–1026.

  • Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E and Polakis P . (1997). Science, 275, 1790–1792.

  • Sakanaka C, Weiss JB and Williams LT . (1998). Proc. Natl. Acad. Sci. USA, 95, 3020–3023.

  • Sakanaka C and Williams LT . (1999). J. Biol. Chem., 274, 14090–14093.

  • Sekido Y, Sato M, Usami N, Shigemitsu K, Mori S, Maeda O, Yokoi T, Hasegawa Y, Yoshioka H and Shimokata K . (2002). Cancer Genet. Cytogenet., 132, 33–42.

  • Shigemitsu K, Sekido Y, Usami N, Mori S, Sato M, Horio Y, Hasegawa Y, Bader SA, Gazdar AF, Minna JD, Hida T, Yoshioka H, Imaizumi M, Ueda Y, Takahashi M and Shimokata K . (2001). Oncogene, 20, 4249–4257.

  • Shivapurkar N, Virmani AK, Wistuba, II, Milchgrub S, Mackay B, Minna JD and Gazdar AF . (1999). Clin. Cancer Res., 5, 17–23.

  • Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, Tornielli S, Pilotti S, De Gregorio L, Pastorino U, Pierotti MA, Ohta M, Huebner K and Croce CM . (1996). Cell, 85, 17–26.

  • Su LK, Vogelstein B and Kinzler KW . (1993). Science, 262, 1734–1737.

  • Sunaga N, Kohno T, Kolligs FT, Fearon ER, Saito R and Yokota J . (2001). Genes Chromosomes Cancer, 30, 316–321.

  • Taguchi T, Jhanwar SC, Siegfried JM, Keller SM and Testa JR . (1993). Cancer Res., 53, 4349–4355.

  • Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, Nagorney DM, Burgart LJ, Roche PC, Smith DI, Ross JA and Liu W . (2002). Oncogene, 21, 4863–4871.

  • Tetsu O and McCormick F . (1999). Nature, 398, 422–426.

  • Tiainen M, Tammilehto L, Mattson K and Knuutila S . (1988). Cancer Genet. Cytogenet., 33, 251–274.

  • van Gijn ME, Snel F, Cleutjens JP, Smits JF and Blankesteijn WM . (2001). Exp. Cell Res., 265, 46–53.

  • Wistuba, II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L, Fondon JW 3rd, Garner HR, McKay B, Latif F, Lerman MI, Lam S, Gazdar AF and Minna JD . (2000). Cancer Res., 60, 1949–1960.

  • Yost C, Torres M, Miller JR, Huang E, Kimelman D and Moon RT . (1996). Genes Dev., 10, 1443–1454.

  • Zhang Z, Hartmann H, Do VM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Sommer B, van de Wetering M, Clevers H, Saftig P, De Strooper B, He X and Yankner BA . (1998). Nature, 395, 698–702.

Download references

Acknowledgements

We thank Dr Bert Vogelstein for the pGL3-OT and pGL3-OF reporter plasmids, Dr Adi F Gazdar for the NCI-H1299 cell line, and Ms Hiroko Kako and Ms Yumie Narita for technical support. This work was supported in part by a Grant-in-Aid from the Japan Society for the Promotion of Science to YS, and NCI Grants P50 CA70907 and CA71618 to JDM.

Author information

Authors and Affiliations

  1. Department of Clinical Preventive Medicine, Nagoya University School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya, 466-8550, Japan

    Noriyasu Usami, Yoshitaka Sekido, Osamu Maeda & Kaoru Shimokata

  2. Department of Thoracic Surgery, Nagoya University School of Medicine, Nagoya, 466-8550, Japan

    Noriyasu Usami, Hiromu Yoshioka, Munehisa Imaizumi & Yuichi Ueda

  3. Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, 466-8550, Japan

    Osamu Maeda, Kazuhito Yamamoto, Yoshinori Hasegawa & Kaoru Shimokata

  4. Department of Pathology II, Nagoya University School of Medicine, Nagoya, 466-8550, Japan

    Masahide Takahashi

  5. Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, 75235, TX, USA

    John D Minna

Authors
  1. Noriyasu Usami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshitaka Sekido
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Osamu Maeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazuhito Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John D Minna
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshinori Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiromu Yoshioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Munehisa Imaizumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yuichi Ueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masahide Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kaoru Shimokata
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshitaka Sekido.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Usami, N., Sekido, Y., Maeda, O. et al. β-catenin inhibits cell growth of a malignant mesothelioma cell line, NCI-H28, with a 3p21.3 homozygous deletion. Oncogene 22, 7922–7930 (2003). https://doi.org/10.1038/sj.onc.1206533

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206533

Keywords

This article is cited by

Search

Advanced search

Quick links